secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001213900-23-065597
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell Q2 sales down 9% to $3.5M; net loss widens to $1.4M from $684K
-----------------------------------------------------------------------

- Product sales $3.5M in Q2 2023 vs $3.9M in Q2 2022 (-9%); gross margin fell to 30% from 44%.
- Net loss $(1.4M) or $(0.18)/share vs $(0.684M) or $(0.09)/share in prior-year quarter.
- Six-month net loss widened to $(3.7M) from $(171K); EBITDA turned negative $(2.2M) vs positive $1.2M.
- Cash dropped to $1.5M from $5.8M at Dec 31, 2022; raised $3M debt facility with 7-year amortization.
- CEO cites production contamination remediation; goal to reach ~$6M quarterly output (80% of $30M capacity).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390023065597/0001213900-23-065597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390023065597/ea183184-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-065597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer